Kapil Vikas, Jain Ajay K, Lobo Melvin D
William Harvey Heart Centre, NIHR Cardiovascular Biomedical Research Unit, Centre for Clinical Pharmacology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Barts Hypertension Clinic, Department of Clinical Pharmacology, Barts Health NHS Trust, London, UK.
Interv Cardiol. 2014 Mar;9(1):54-61. doi: 10.15420/icr.2011.9.1.54.
Resistant hypertension is associated with high morbidity and mortality despite numerous pharmacological strategies. A wealth of preclinical and clinical data have demonstrated that resistant hypertension is associated with elevated renal and central sympathetic tone. The development of interventional therapies to modulate the sympathetic nervous system potentially represents a paradigm shift in the strategy for blood pressure control in this subset of patients. Initial first-in-man and pivotal, randomised controlled trials of endovascular, radio-frequency renal sympathetic denervation have spawned numerous iterations of similar technology, as well as many novel concepts for achieving effective renal sympatholysis. This review details the current knowledge of these devices and the evidence base behind each technology.
尽管有众多药物治疗策略,但顽固性高血压仍与高发病率和死亡率相关。大量临床前和临床数据表明,顽固性高血压与肾脏和中枢交感神经张力升高有关。开发调节交感神经系统的介入疗法可能代表了这部分患者血压控制策略的范式转变。血管内射频肾交感神经消融术的首次人体试验和关键随机对照试验催生了许多类似技术的迭代,以及许多实现有效肾交感神经溶解的新概念。这篇综述详细介绍了这些设备的当前知识以及每种技术背后的证据基础。